N-乙酰基-3-(4-氯苯甲酰基)-4-哌啶酮 | 144507-32-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: N-乙酰基-3-(4-氯苯甲酰基)-4-哌啶酮
• 英文名称: N-acetyl-3-(4-chlorobenzoyl)-4-piperidone
• 英文别名: 1-acetyl-3-(4-chlorobenzoyl)piperidin-4-one
• CAS: 144507-32-4
• 化学式: C₁₄H₁₄ClNO₃
• 分子量: 279.723
• InChiKey: BIIUJWQKTIKMRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  54.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-乙酰基-3-(4-氯苯甲酰基)-4-哌啶酮 在 肼 作用下， 以 乙醇 为溶剂， 以41 g的产率得到1-[3-(4-chlorophenyl)-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone
  参考文献：
  名称：

  Nonpeptidic, Noncovalent Inhibitors of the Cysteine Protease Cathepsin S

  摘要：

  The first nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S (CatS) are described. Electronic database searching using the program DOCK generated a screening set of potential CatS inhibitors from which two lead structures were identified as promising starting points for a drug discovery effort. Lead optimization afforded potent (IC50 < 50 nM) and selective inhibitors of CatS demonstrating cellular activity and reversibility of enzyme inhibition.

  DOI：

  10.1021/jm0496133
• 作为产物：
  描述：

  N-乙酰基-4-哌啶酮 在 盐酸 、 对甲苯磺酸 、 三乙胺 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 13.0h， 生成 N-乙酰基-3-(4-氯苯甲酰基)-4-哌啶酮
  参考文献：
  名称：

  Nonpeptidic, Noncovalent Inhibitors of the Cysteine Protease Cathepsin S

  摘要：

  The first nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S (CatS) are described. Electronic database searching using the program DOCK generated a screening set of potential CatS inhibitors from which two lead structures were identified as promising starting points for a drug discovery effort. Lead optimization afforded potent (IC50 < 50 nM) and selective inhibitors of CatS demonstrating cellular activity and reversibility of enzyme inhibition.

  DOI：

  10.1021/jm0496133

文献信息

• Novel tetrahydropyrido[4,3-d]pyrimidines as gastric antilesion agents
  作者：PJ Sanfilippo、M Urbanski、L Williams、JB Press、LB Katz、DA Shriver、JA Fernandez、D Shatynski、SJ Offord

  DOI：10.1016/0223-5234(92)90085-f

  日期：1992.10

  A variety of substituted tetrahydropyrido[4,3-d]pyrimidines was prepared and found to possess gastric antilesion against ethanol-induced lesions in rats. The more potent compounds possessed similar activity against aspirin-induced gastric lesions. A selective group of compounds was determined to be inactive as gastric antisecretory agents in rabbit isolated parietal cells. The antilesion properties of these tetrahydropyrido[4,3-d]pyrimidines make them a potential alternative to prostaglandin therapy for gastric antilesion therapy and may have clinical utility in peptic ulcer disease.
• Synthesis, in vitro [3H]prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines, a new class of antihypertensive agents
  作者：Giorgio Winters、Alberto Sala、Domenico Barone、Emiliana Baldoli

  DOI：10.1021/jm00145a015

  日期：1985.7

  A series of new 3-aryl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridines was synthesized and screened for in vitro [3H]prazosin displacement activity. The results correlated well with their antihypertensive activity in spontaneous hypertensive rats. 1-Benzyl-3-(4-fluorophenyl)-4,5,6,7-tetrahydropyrazolo[4,3-c]pyrid ine (50, L 16052) was selected for further pharmacological evaluations of its potency when administered orally to conscious renal hypertensive dogs.
• Nonpeptidic, Noncovalent Inhibitors of the Cysteine Protease Cathepsin S
  作者：Robin L. Thurmond、Mary Pat Beavers、Hui Cai、Steven P. Meduna、Darin J. Gustin、Siquan Sun、Harold J. Almond、Lars Karlsson、James P. Edwards

  DOI：10.1021/jm0496133

  日期：2004.9.1

  The first nonpeptidic, noncovalent inhibitors of the cysteine protease cathepsin S (CatS) are described. Electronic database searching using the program DOCK generated a screening set of potential CatS inhibitors from which two lead structures were identified as promising starting points for a drug discovery effort. Lead optimization afforded potent (IC50 < 50 nM) and selective inhibitors of CatS demonstrating cellular activity and reversibility of enzyme inhibition.